The global community acquired bacterial pneumonia (CABP) treatment market is expected to garner a market value of USD 5 billion in 2023 and is expected to accumulate a market value of USD 8.38 billion by registering a CAGR of 5.3% in the forecast period 2023 to 2033. The market for community acquired bacterial pneumonia (CABP) treatment registered a CAGR of 3.2% in the historical period 2018 to 2022.
The market for community acquired bacterial pneumonia (CABP) treatment is expected to experience steady growth in the coming years, driven by several factors. CABP is a type of pneumonia that is acquired outside of a hospital or healthcare setting and is caused by bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Legionella pneumophila.
The global CABP treatment market includes a variety of drugs such as macrolides, fluoroquinolones, tetracyclines, and cephalosporins, which are used to treat bacterial infections. The market is expected to be driven by an increase in the incidence of CABP, an aging population, and the development of new and innovative drugs to treat the condition.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 5 Billion |
| Anticipated Forecast Value (2033) | USD 8.38 Billion |
| Projected Growth Rate (2023 to 2033) | 5.3% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to market research and competitive intelligence provider, Future Market Insights- the market for community acquired bacterial pneumonia (CABP) treatment reflected a value of 3.2% during the historical period, 2018 to 2022. The incidence of CABP is increasing globally, driven by factors such as smoking, chronic obstructive pulmonary disease (COPD), and an aging population. This has led to an increase in demand for CABP treatment, driving the growth of the market.
Key players in the market are focused on developing new and innovative drugs to treat CABP, which is expected to drive the growth of the market. The availability of effective antibiotics is also expected to contribute to the growth of the market. Furthermore, Increasing healthcare spending in developing countries is expected to drive the growth of the market in these regions. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, driven by the large population and increasing healthcare spending in countries such as India and China.
Overall, the market for community acquired bacterial pneumonia (CABP) treatment is expected to register a CAGR of 5.3% in the forecast period 2023 to 2033.
Increasing Prevalence of Community Acquired Bacterial Pneumonia (CABP) to push market growth
An increase in the incidence of Community Acquired Bacterial Pneumonia (CABP) is expected to drive the growth of the CABP treatment market. CABP is a common type of pneumonia that is acquired outside of a hospital or healthcare setting and is caused by bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Legionella pneumophila.
The incidence of CABP is increasing globally due to factors such as smoking, chronic obstructive pulmonary disease (COPD), and an aging population. According to studies, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In addition to this, approximately 650 adults are hospitalized with CAP every year per 100,000 population in the United States, corresponding to 1.5 million unique CAP hospitalizations each year. As the incidence of CABP increases, the demand for CABP treatment is also expected to increase, which is likely to drive the growth of the market.
Moreover, the availability of effective antibiotics and the development of new and innovative drugs to treat CABP are also expected to contribute to the growth of the market.
In addition to these factors, increasing healthcare spending in developing countries and the presence of advanced healthcare infrastructure in developed regions are also expected to drive the growth of the CABP treatment market. Overall, the CABP treatment market is expected to experience steady growth in the coming years, driven by an increase in the incidence of CABP and other factors.
Expensive Cost of Treatment to restrict Market Growth
The cost of treatment for community acquired bacterial pneumonia (CABP) can be high, particularly for advanced cases that require more invasive procedures. This can make it difficult for some patients to afford treatment, which can limit market growth.
Additionally, despite increasing awareness of Community Acquired Bacterial Pneumonia (CABP), there is still a lack of knowledge and understanding about the condition among the general population. This can lead to delays in diagnosis and treatment, which can impact the growth of the market.
Moreover, the regulatory requirements for approval of new treatments for Community Acquired Bacterial Pneumonia (CABP) can be stringent, which can limit the number of treatments that make it to market. This can impact the availability of new and innovative treatments for patients.
Increasing awareness and diagnosis of the condition Shaping Landscape for CABP Treatment in South & East Asia
The South and East Asia region is a growing market for community acquired bacterial pneumonia (CABP) treatment. The region includes countries such as India, China, Japan, South Korea, and the ASEAN countries. The market is driven by the increasing prevalence of CABP and the growing demand for effective treatments in the region.
This growth can be attributed to factors such as the increasing aging population, high burden of respiratory diseases, and increasing healthcare spending in countries such as India and China.
In India, the prevalence of CABP is high, especially among the elderly and immunocompromised populations. The market is witnessing the entry of new players, including local and international pharmaceutical companies, which is expected to increase competition and innovation in the market.
In China, the prevalence of CABP is also high, driven by factors such as air pollution, smoking, and an aging population. The government is taking steps to improve healthcare infrastructure and increase access to healthcare services, which is expected to drive the growth of the market.
Overall, the CABP treatment market in the South and East Asia region is turning out to be a promising market with significant growth potential. The increasing prevalence of CABP and the growing demand for effective treatments are expected to drive the growth of the market in the region in the coming years.
Increasing Focus on Technological Advancements Shaping Landscape for CABP Treatment in North America
The incidence of CABP is high in North America, particularly in the elderly and immunocompromised populations. This has led to a high demand for effective CABP treatments in the region. North America has a significant pipeline of new antibiotics under development for the treatment of CABP. This has led to the availability of new and effective treatments, which is expected to drive the growth of the market.
Furthermore, North America has a strong healthcare infrastructure, with well-trained healthcare providers and access to advanced medical technologies. This has helped to support the development and adoption of new treatments for Community Acquired Bacterial Pneumonia (CABP).
Overall, these factors are driving the growth of the Community Acquired Bacterial Pneumonia (CABP) Treatment market in North America. However, there are still challenges facing the market, including high treatment costs and the need for more effective and targeted therapies. Nonetheless, the market is expected to continue growing as new treatments and technologies are developed and as the awareness of community acquired bacterial pneumonia (CABP) continues to increase.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Intravenous (IV) route of administration to hold a significant share and push market growth
Among the different treatments for community acquired bacterial pneumonia (CABP), the intravenous (IV) route of administration is likely to account for a significant share of the market.
This is because IV antibiotics are often the first-line treatment for severe cases of CABP, where prompt and effective treatment is critical for improving patient outcomes. IV antibiotics can rapidly achieve therapeutic levels in the bloodstream, leading to a faster resolution of symptoms and a shorter hospital stay.
Additionally, IV antibiotics can be administered in a hospital or outpatient setting, depending on the severity of the illness, which adds to the convenience of treatment for patients.
Overall, while the IV route of administration is likely to account for a significant share of the CABP treatment market, the inhaled route of administration is an emerging segment that is expected to gain traction in the coming years.
Hospital pharmacies segment to hold a significant share and push market growth
Hospital pharmacies play a critical role in the management of CABP, as they are often the first point of contact for patients with CABP. Hospital pharmacies provide access to a wide range of medications and specialized treatment options, including invasive procedures and advanced imaging techniques, which are essential for the management of CABP.
In addition, hospital pharmacies have access to a multidisciplinary team of healthcare professionals, including physicians, nurses, and pharmacists, who can collaborate to provide comprehensive care to patients with CABP. This team-based approach is critical for the management of CABP, as it allows for individualized treatment plans that address the unique needs of each patient
Key players in the market include companies such as Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 5 billion |
| Market Value in 2033 | USD 8.38 billion |
| Growth Rate | CAGR of 5.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Route of Administration, Dose Form, Drug Class, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Nabriva Therapeutics; Melinta Therapeutics; Wakunaga Pharmaceutical Co. Ltd.; Actavis Generics; Pfizer Inc.; Paratek Pharmaceuticals; Cumberland Pharmaceuticals Inc.; Theravance Biopharma Inc.; Merck Sharp & Dohme Inc.; Cubist Pharmaceuticals LLC (Merck); Shionogi Inc.; Allergan Plc.; Eagle Pharmaceuticals Inc.; Combioxin; TiGenix |
| Customization | Available Upon Request |
In 2023, the market may potentially be worth USD 5 billion.
The market may steadily transform at a CAGR of 5.3% through 2033.
The market registered a HCAGR of 3.2 between 2018 and 2022.
The estimated value of the global market in 2033 is USD 8.38 billion.
Hospital pharmacies are poised to capture a considerable market share.
| Projected Forecast Value (2023) | USD 4,024.7 million |
|---|---|
| Projected Forecast Value (2033) | USD 7,948.6 million |
| Growth rate (2023 to 2033) | 7.0% CAGR |
| Expected Market Value in 2023 | USD 1.4 Billion |
|---|---|
| Projected Market Value in 2033 | USD 2.6 Billion |
| Growth Rate (2023 to 2033) | CAGR of 6.4% |
| Estimated Market Value (2022) | USD 521.1 Million |
|---|---|
| Projected Market Value (2032) | USD 899.4 Million |
| Value-based CAGR (2022 to 2032) | 5.6% |
Explore Therapy Area Insights
View Reports
Community Acquired Bacterial Pneumonia (CABP) Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
